Evidence map›Paper›PMID 26774156›Full record

ArticleInternational journal of antimicrobial agents2016

Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota.

Laura J Sherrard, Stef J McGrath, Leanne McIlreavey, Joseph Hatch, Matthew C Wolfgang, Marianne S Muhlebach, Deirdre F Gilpin, J Stuart Elborn, Michael M Tunney

Abstract read
In one paragraph

Article in International journal of antimicrobial agents, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Journal of bacteriology · 2026
    Review
  3. Article
  4. Article
  5. BioMed research international · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.Journal of the Pediatric Infectious Diseases Society · 2022
    Review
  17. Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  18. Journal of medical microbiology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Laura J SherrardCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK. Electronic address: lsherrard03@qub.ac.uk.
Stef J McGrathCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK.
Leanne McIlreaveyCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK.
Joseph HatchCystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Matthew C WolfgangDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Marianne S MuhlebachDepartment of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deirdre F GilpinCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK.
J Stuart ElbornCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; Centre for Infection & Immunity, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, Belfast, UK.
Michael M TunneyCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK; School of Pharmacy, Queen's University Belfast, Belfast, UK.
Queen's University Belfast · GBUniversity of North Carolina at Chapel Hill · US

Funding

The Mucus Transport Apparatus: Why Two Layers?P50HL084934 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2006 to 2010
$15.6M
The Role of Anaerobic Bacterial Infection in Cystic FibrosisR01HL092964 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2010 to 2013
$2.9M
NHLBI NIH HHS 5R01 HL092964-04NHLBI NIH HHS HL084934NHLBI NIH HHS HL092964NHLBI NIH HHS P50 HL084934NHLBI NIH HHS R01 HL092964
6 · The paper itself

Abstract

Extended-spectrum β-lactamase (ESBL) production and the prevalence of the β-lactamase-encoding gene blaTEM were determined in Prevotella isolates (n=50) cultured from the respiratory tract of adults and young people with cystic fibrosis (CF). Time-kill studies were used to investigate the concept of passive antibiotic resistance and to ascertain whether a β-lactamase-positive Prevotella isolate can protect a recognised CF pathogen from the action of ceftazidime in vitro. The results indicated that approximately three-quarters (38/50; 76%) of Prevotella isolates produced ESBLs. Isolates positive for ESBL production had higher minimum inhibitory concentrations (MICs) of β-lactam antibiotics compared with isolates negative for production of ESBLs (P<0.001). The blaTEM gene was detected more frequently in CF Prevotella isolates from paediatric patients compared with isolates from adults (P=0.002), with sequence analysis demonstrating that 21/22 (95%) partial blaTEM genes detected were identical to blaTEM-116. Furthermore, a β-lactamase-positive Prevotella isolate protected Pseudomonas aeruginosa from the antimicrobial effects of ceftazidime (P=0.03). Prevotella isolated from the CF respiratory microbiota produce ESBLs and may influence the pathogenesis of chronic lung infection via indirect methods, including shielding recognised pathogens from the action of ceftazidime.

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCeftazidimeChildCystic FibrosisFemaleHumansMaleMicrobial Sensitivity TestsMicrobial ViabilityMiddle AgedAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCeftazidimeAnaerobesAntibiotic resistanceCystic fibrosisβ-Lactams

Identifiers

PMID26774156
PMCPMC4746055
OpenAlexW2199703742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.